Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

(2011) S. Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Pitfalls in the external validation of FRAX

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

(2010) O. Ström et al.   BONE

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®

(2010) John A. Kanis et al.   BONE

Vertebral fracture assessment using a semiquantitative technique

(2010) Harry K. Genant et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

(2009) Richard Eastell et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial

(2009) R. Eastell et al.   OSTEOPOROSIS INTERNATIONAL

The potential impact of new National Osteoporosis Foundation guidance on treatment patterns

(2009) B. Dawson-Hughes et al.   OSTEOPOROSIS INTERNATIONAL

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL